Neutron Delay Overshadows Strong Q4, Driving Rocket Lab Stock Lower

What happened

Rocket Lab's stock continued its post-earnings decline as the delay in the Neutron rocket development overshadowed a strong Q4 2025 performance with record revenue and backlog growth. The Q4 beat demonstrated execution strength in Space Systems and launch services, but investor focus has shifted decisively to Neutron's revised timeline. According to the DeepValue report, Neutron is re-baselined for a Q4 2026 first launch after a January 2026 tank rupture, a critical milestone that carries high risk of further slippage. The report explicitly flags Neutron delays beyond Q4 2026 as a thesis breaker, potentially triggering increased dilution and pushing the stock toward its bear case value of $45. This market reaction validates the report's warning that Neutron timeline credibility is the dominant swing factor, outweighing near-term operational successes.

Implication

The post-earnings slide underscores that Rocket Lab's valuation is tightly tethered to Neutron's schedule, making operational wins insufficient to offset development uncertainties. Monitoring dated milestones, such as AFP-built tank qualification, is crucial to assess schedule credibility and avoid potential downgrades to the bear case. If Neutron slips beyond Q4 2026, it could trigger the report's downside scenario, leading to further dilution and a stock price closer to $45. While Space Systems backlog conversion, guided for $185M–$200M in Q1 2026, offers some support, the company's history of cash burn and equity issuance adds per-share value risk. Investors are advised to adhere to the report's 'WAIT' rating, delaying entry until Neutron shows concrete progress and dilution trends improve.

Thesis delta

The news reinforces the DeepValue report's core thesis that Neutron timeline risks are paramount and that strong backlog conversion alone cannot justify current valuations. No shift in the investment call is needed, but the market reaction amplifies the urgency of monitoring for further delays or contract accounting issues. Investors should maintain a cautious stance, prioritizing evidence from Q1 2026 results and Neutron milestone updates over headline revenue beats.